Article

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells

2020-05-26

Abstract excerpt

<h4>ABSTRACT</h4> Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancer to treat. Due to the asymptomatic nature of the disease and ineffective drug treatment modalities, the survival rate of PDAC patients remains one of the lowest. The recurrent genetic alterations in PDAC are yet to be targeted; therefore, identifying effective therapeutic combinations is desperately needed. Here, w...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6fb6e54e-ac0e-5f46-b2be-f36ef6d147e1
DOI: 10.1101/2020.05.25.112896

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cellsDOI 10.1101/2020.05.25.112896Read

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cellsSemantic proximity Read

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtypeSemantic proximity Read

Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.Semantic proximity Read

Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.Semantic proximity Read

Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC.Semantic proximity Read

Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer CellsSemantic proximity Read

DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical PerspectivesSemantic proximity Read

Targeting APE1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancerSemantic proximity Read

PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerSemantic proximity Read

Base-excision repair pathway regulates transcription-replication conflicts in pancreatic ductal adenocarcinomaSemantic proximity Read

Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinomaSemantic proximity Read

TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stressSemantic proximity Read